Jimenez vows Novartis-wide GMP standard; Catalent expands in Germany;

> "We are committed to ensuring one single high quality standard across Novartis and will invest the necessary resources to achieve this goal in all divisions," said Novartis ($NVS) CEO Joe Jimenez in a financial filing. Story

> Catalent Pharma said it is expanding its Schorndorf, Germany facility, adding R&D and commercial-scale fluid bed technology, OptiMelt hot-melt extrusion and cGMP compliance upgrades. Release

> CMO Patheon has elevated Antonella Mancuso to president, global commercial operations and chief manufacturing officer. Release

> The FDA has added Tromethamine, made by Hospira ($HSP), to the list of resolved drug shortages. Listing.

> Supply chain industry group GS1 is readying a pilot project in Thailand for use of bar codes on nutritional ingredients. Story

> The DEA has registered AMPAC Fine Chemicals as a manufacturer of controlled substances. Article

> Washington state pharmacies were raided by federal officials on suspicion they were reselling drugs that had been returned. Story

> Thin Film Electronics and PST Sensors will collaborate to develop a printed sensor system that monitors the temperature of in-transit pharmaceuticals and foods. Article

 

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.